Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg for an undisclosed amount. “This strategic acquisition is a key step for our ongoing expansion in the high-growth biopharmaceuticals market,” said Auguste Willems, a member of Wacker’s executive board. “The new plant will enable us to satisfy robust market demand today and in the coming years and ...